On July 31, 2019 Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, reported it will be featured as a presenting company at the Canaccord Genuity 39th Annual Growth Conference on Wednesday, August 7, 2019 in Boston, MA (Press release, Eleven Biotherapeutics, JUL 31, 2019, View Source [SID1234537938]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Canaccord Genuity 39th Annual Growth Conference
Date: August 7, 2019
Time: 10 a.m. EDT
Location: San Francisco room, The InterContinental Boston Hotel in Boston

A live webcast of the company’s presentation will be accessible from the Investors & Media section of Sesen Bio’s website, www.sesenbio.com. An archived replay of the webcast will be available on the company’s website for 90 days after the conference.